Neuropsychologic Impact of MOGAD: A Patient Reported Outcomes Study
Journal: Neurology; October 8, 2024
Author(s): Bruna Leles Vieira de Souza, Yihan Zhang, Rebecca Salky, Monique Anderson, Takahisa Mikami, Rebecca Gillani, Mattia Wruble, Gabriela Romanow, Anastasia Vishnevetsky, and Giovanna Manzano
How do MOGAD patients report their own quality of life?
People living with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) experience not only physical symptoms like vision problems or weakness but also emotional and mental challenges that affect their daily lived experience. This study, which was ongoing at the time the abstract was published for a conference, collected information reported by 20 patients aged over 13 years via surveys. The surveys assessed how MOGAD affects things like mood, anxiety, and thinking abilities over time. It also tested how these aspects of daily life and abilities differed with the type of MOGAD and the MOG antibody levels. This type of information is also known as patient-reported outcomes measures, or PROMS.
The results showed that people with relapsing MOGAD and those with eye inflammation (or optic neuritis) reported higher levels of depression and anxiety compared with other patients. Levels of MOG antibodies and side effects from steroid treatment did not meaningfully change how patients rated their symptoms, daily functioning, or overall well-being. This study shows that patients’ own reports, or PROMS, can be a meaningful way to assess mental health and quality of life in MOGAD care.
Free Access: Abstract only
